BioMarin Pharmaceutical Inc. (BMRN) Outlook Lowered By Leerink

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the cheap healthcare stocks to bargain heading into 2026. As reported by TheFly, Leerink reduced the terms people connected BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $60 from $82 and downgraded it to Market Perform from Outperform connected December 3.

According to the analyst, the actions taken by caller leadership, including workforce cuts and discontinuing the Roctavian program, fortify its semipermanent position. However, rising competitory unit successful achondroplasia and a important spread successful the company’s pipeline volition marque M&A necessary, the expert noted, adding that this creates uncertainty astir whether these measures are capable to boost the banal from its existent level.

Earlier connected November 3, Bernstein besides lowered the terms people connected BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $88 from $95, with a ‘Market Perform’ rating. The expert noted the company’s quarterly performance, successful which the institution delivered gross successful enactment with expectations but missed its EPS target.

Overall, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has the bulk of analysts assigning it a ‘Buy’ oregon equivalent rating, with a people terms going arsenic precocious arsenic $122 and arsenic debased arsenic $55, arsenic of December 7. The median terms people of $91 suggests an upside imaginable of astir 70%.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is simply a California-based biotechnology institution that develops and markets therapies for superior uncommon diseases. The company’s halfway offerings see VIMIZIM, VOXZOGO, NAGLAZYME, and PALYNZIQ.

While we admit the imaginable of BMRN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.